<div id="readability-page-1"><p>H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $117.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Tsao covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Rezolute, and Xenon. According to TipRanks, Tsao has an average return of <span>21.2%</span> and a 52.10% success rate on recommended stocks. </p> <p>In addition to H.C. Wainwright, Protagonist Therapeutics also received a Buy from Barclays’s Etzer Darout in a report issued today. However, on the same day, Goldman Sachs maintained a Hold rating on Protagonist Therapeutics (NASDAQ: PTGX).</p></div>

PTGX

LABU

<p>H.C. Wainwright analyst Douglas Tsao has reaffirmed a Buy rating for Protagonist Therapeutics (PTGX) with a price target of $117.00. Tsao, who specializes in the Healthcare sector, has an average return of 21.2% and a 52.10% success rate on his stock recommendations. Additionally, Barclays analyst Etzer Darout also issued a Buy rating for the company, while Goldman Sachs maintained a Hold rating on the stock.</p>

Tip Ranks

Protagonist Therap

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

iShares US Pharma

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VG Health

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Pacira BioSciences

Rezolute

Xenon Pharma

Barclays

Goldman Sachs

GS Hldg R

H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)